$-0.41 EPS Expected for Chimerix (CMRX); Shorts at Reynolds American (RAI) Lowered By 2.14%

July 25, 2017 - By Hazel Jackson

Reynolds American Incorporated (NYSE:RAI) had a decrease of 2.14% in short interest. RAI’s SI was 9.38M shares in July as released by FINRA. Its down 2.14% from 9.59 million shares previously. With 7.26 million avg volume, 1 days are for Reynolds American Incorporated (NYSE:RAI)’s short sellers to cover RAI’s short positions. The SI to Reynolds American Incorporated’s float is 1.14%. It is 0.00% or $0 reaching $0 per share. It is down 33.47% since July 25, 2016 and is uptrending. It has outperformed by 16.77% the S&P500.

Analysts expect Chimerix Inc (NASDAQ:CMRX) to report $-0.41 EPS on August, 14.They anticipate $0.02 EPS change or 5.13% from last quarter’s $-0.39 EPS. After having $-0.38 EPS previously, Chimerix Inc’s analysts see 7.89% EPS growth. About 77,905 shares traded. Chimerix Inc (NASDAQ:CMRX) has risen 3.54% since July 25, 2016 and is uptrending. It has underperformed by 13.16% the S&P500.

Among 7 analysts covering Chimerix Inc (NASDAQ:CMRX), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Chimerix Inc had 16 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Monday, October 5. Piper Jaffray maintained Chimerix Inc (NASDAQ:CMRX) on Monday, December 28 with “Overweight” rating. Morgan Stanley downgraded the shares of CMRX in report on Tuesday, February 23 to “Underweight” rating. The firm earned “Mkt Perform” rating on Monday, December 28 by FBR Capital. The stock has “Outperform” rating by FBR Capital on Tuesday, August 18. Barclays Capital downgraded Chimerix Inc (NASDAQ:CMRX) on Tuesday, February 23 to “Equal-Weight” rating. Citigroup initiated the stock with “Buy” rating in Thursday, September 3 report. Brean Capital maintained it with “Buy” rating and $57 target in Thursday, August 6 report. FBR Capital maintained Chimerix Inc (NASDAQ:CMRX) rating on Tuesday, February 23. FBR Capital has “Mkt Perform” rating and $10 target. Barclays Capital maintained Chimerix Inc (NASDAQ:CMRX) rating on Tuesday, December 29. Barclays Capital has “Overweight” rating and $12 target.

Investors sentiment decreased to 0.94 in 2016 Q4. Its down 0.11, from 1.05 in 2016Q3. It turned negative, as 16 investors sold Chimerix Inc shares while 31 reduced holdings. 12 funds opened positions while 32 raised stakes. 30.20 million shares or 8.41% less from 32.97 million shares in 2016Q3 were reported. Goldman Sachs Grp stated it has 0% in Chimerix Inc (NASDAQ:CMRX). Virginia Retirement Systems Et Al holds 26,300 shares or 0% of its portfolio. Prudential Fin owns 0% invested in Chimerix Inc (NASDAQ:CMRX) for 248,740 shares. Moreover, Invesco Ltd has 0% invested in Chimerix Inc (NASDAQ:CMRX) for 70,016 shares. Blackrock Investment Mngmt Limited Company invested in 0% or 184,679 shares. California Public Employees Retirement System stated it has 0% of its portfolio in Chimerix Inc (NASDAQ:CMRX). Moreover, Cubist Systematic Strategies Ltd Liability Corp has 0.01% invested in Chimerix Inc (NASDAQ:CMRX) for 15,100 shares. Citigroup Inc invested in 45,470 shares or 0% of the stock. Retail Bank Of Montreal Can owns 37,852 shares or 0% of their US portfolio. State Street Corporation invested in 751,031 shares. Sabby Limited Liability Corp stated it has 79,900 shares. Panagora Asset Mgmt holds 0.01% of its portfolio in Chimerix Inc (NASDAQ:CMRX) for 286,590 shares. Fmr Ltd Limited Liability Company has 6.94M shares for 0% of their portfolio. Rockefeller Fin Svcs owns 16,973 shares or 0% of their US portfolio. 50,950 are held by Tudor Inv Et Al.

Chimerix, Inc. is a biotechnology company. The company has market cap of $255.14 million. The Firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. It currently has negative earnings. The Company’s lead compound, brincidofovir, is in development as an oral and intravenous formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Among 17 analysts covering Reynolds American Inc. (NYSE:RAI), 5 have Buy rating, 2 Sell and 10 Hold. Therefore 29% are positive. Reynolds American Inc. had 35 analyst reports since July 29, 2015 according to SRatingsIntel. S&P Research upgraded Reynolds American, Inc. (NYSE:RAI) on Wednesday, July 29 to “Strong Buy” rating. Jefferies initiated the stock with “Buy” rating in Wednesday, September 21 report. The stock of Reynolds American, Inc. (NYSE:RAI) earned “Underperform” rating by CLSA on Wednesday, October 21. The rating was maintained by Jefferies with “Hold” on Monday, July 17. As per Monday, June 5, the company rating was maintained by Jefferies. The firm earned “Market Perform” rating on Friday, February 10 by Cowen & Co. As per Friday, August 14, the company rating was downgraded by Zacks. The firm has “Neutral” rating by Goldman Sachs given on Monday, September 12. The rating was maintained by RBC Capital Markets with “Hold” on Friday, June 23. Goldman Sachs downgraded it to “Buy” rating and $54 target in Wednesday, March 16 report.

Since March 3, 2017, it had 0 insider purchases, and 9 sales for $12.48 million activity. Another trade for 5,586 shares valued at $338,938 was made by Hawley Nancy H. on Monday, March 13. $1.71 million worth of Reynolds American, Inc. (NYSE:RAI) was sold by CALDWELL LISA J on Monday, March 13. $1.39M worth of Reynolds American, Inc. (NYSE:RAI) was sold by Herko Daniel J. on Monday, March 13. Crew Debra Ann sold $1.06M worth of stock. Smothers Frederick W sold $961,759 worth of stock. 7,804 shares were sold by Auger Michael P., worth $473,519. 38,519 shares were sold by Holton Martin L. III, worth $2.34 million on Monday, March 13.

Reynolds American Inc. is a holding company. The company has market cap of $. The Company’s divisions include RJR Tobacco, which consists of the primary activities of its subsidiary, R. It currently has negative earnings. J.

Investors sentiment decreased to 0.75 in Q4 2016. Its down 0.14, from 0.89 in 2016Q3. It turned negative, as 89 investors sold Reynolds American, Inc. shares while 298 reduced holdings. 119 funds opened positions while 170 raised stakes. 661.97 million shares or 2.94% more from 643.05 million shares in 2016Q3 were reported. Commerzbank Aktiengesellschaft Fi has 0.75% invested in Reynolds American, Inc. (NYSE:RAI). Allianz Asset Management Ag invested in 0.11% or 2.25 million shares. Fred Alger has 285 shares. Old Second Bancorporation Of Aurora holds 0.07% or 2,658 shares. 24,023 were reported by Hap Trading Llc. Bb&T Secs Ltd Com owns 0.2% invested in Reynolds American, Inc. (NYSE:RAI) for 287,270 shares. Ameriprise Finance accumulated 3.98 million shares. Moreover, Lombard Odier Asset Mngmt (Europe) Ltd has 0.22% invested in Reynolds American, Inc. (NYSE:RAI) for 10,903 shares. Bp Public Ltd holds 0.1% or 47,000 shares in its portfolio. Halcyon Mgmt Prtn Limited Partnership invested 12.33% of its portfolio in Reynolds American, Inc. (NYSE:RAI). Assetmark Inc holds 0.01% or 11,663 shares. 667,610 were reported by P Schoenfeld Asset Limited Partnership. The Tennessee-based Td Cap Mngmt Ltd Liability Com has invested 0.02% in Reynolds American, Inc. (NYSE:RAI). 869 are owned by First Personal Fincl. Cibc Asset Mngmt Inc has 0.04% invested in Reynolds American, Inc. (NYSE:RAI).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: